Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15636906 | 0.85 | KDM5B (0.41) | LMNAKMT2AMEN1SYKEPHX2 | |
| SCHEMBL15637477 | 0.81 | CCR2 (0.46) | POLB | |
| SCHEMBL18686361 | 0.80 | GPR119 (0.43) | MAPTNPSR1ATMKMT2AMEN1 | |
| SCHEMBL15637263 | 0.80 | KDM5B (0.44) | MAPTKMT2AMEN1SYKKDM5A | |
| SCHEMBL15637130 | 0.77 | PIK3CA (0.42) | MAPTNPSR1KDM5AKDM5CKDM4C | |
| SCHEMBL15635957 | 0.76 | MAPT (0.49) | MAPTNPSR1NOS1NOS2ATM | |
| SCHEMBL15635959 | 0.76 | MAPT (0.49) | MAPTNPSR1NOS1NOS2ATM | |
| SCHEMBL15637029 | 0.76 | KDM5B (0.47) | SYKKDM5AKDM5CKDM4CKDM5B | |
| SCHEMBL18860210 | 0.73 | KDM5B (0.46) | SYKKDM5AKDM5CKDM4CKDM5B | |
| SCHEMBL15637005 | 0.72 | KDM5B (0.42) | SYKEPHX2KDM5AKDM5CKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107434803-B | Inhibitors of histone demethylases | 吉利德科学公司 | 2020-05-05 | — | — | CN | disclosed |
| US-10221139-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10189787-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3023415-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2017-12-06 | — | — | EP | disclosed |
| CN-107434803-A | Histone demethylase inhibitor | 吉利德科学公司 | 2017-12-05 | — | — | CN | disclosed |
| US-20170320827-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2017-11-09 | — | — | US | disclosed |
| EP-3170811-A1 | ETHYL PYRIDINE-4-CARBOXYLATE COMPOUND AS INHIBITOR OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-3150582-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3023415-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2016-05-25 | — | — | EP | disclosed |
| CN-105263906-A | Inhibitors of histone demethylases | EPITHERAPEUTICS APS | 2016-01-20 | — | — | CN | disclosed |
| EP-2961736-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2016-01-06 | — | — | EP | disclosed |
| US-9221801-B2 | Inhibitors of histone demethylases | EPITHERAPEUTICS APS (DK) | 2015-12-29 | — | — | US | disclosed |
| EP-2903968-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Epitherapeutics ApS (DK) | 2015-08-12 | — | — | EP | disclosed |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014131777-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014053491-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | MAPT 3435/4885NPSR1 4113/4885NOS1 1198/4885 |
| US-10189787-B2 | Inhibitors of histone demethylases | EHMT1, KDM1B, EHMT2 | MAPT 3027/4885NPSR1 4188/4885NOS1 1040/4885 |
| US-20150203453-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | MAPT 3016/4885NPSR1 4165/4885NOS1 1047/4885 |
| US-20140371195-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | MAPT 3027/4885NPSR1 4188/4885NOS1 1040/4885 |
| US-20170320827-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | MAPT 3027/4885NPSR1 4188/4885NOS1 1040/4885 |
| US-10221139-B2 | Inhibitors of histone demethylases | EHMT1, KDM1B, EHMT2 | MAPT 3027/4885NPSR1 4188/4885NOS1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.